申请人:Dizal (Jiangsu) Pharmaceutical Co., Ltd.
公开号:US20210009587A1
公开(公告)日:2021-01-14
Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.